UBA1 Mutations Drive RIPK1-Mediated Cell Death and Monocyte Dysfunction in VEXAS Syndrome
Paul BreillatiD, Samuel J. MagazineriD, Stéphane M. CamusiD, Léa DionetiD, Benjamin De ValenceiD, Pierre SohieriD, Amine MajdiiD, Quentin DelcrosiD, Federica Pallotti, Nadia RivetiD, Kevin ChevalieriD, Margot Poux, Pierre‐Louis TharauxiD, Olivia LenoiriD, Abdelrahim ZouediD, Olivier KosmideriD, David B. BeckiD, Benjamin TerrieriD
Abstract
VEXAS syndrome is a severe adult-onset autoinflammatory disease caused by somatic mutations in UBA1 gene, disrupting cytoplasmic ubiquitin-activating enzyme E1 function in hematopoietic progenitors. The pathogenesis remains poorly understood, particularly how UBA1 mutations perturb myeloid function. Here, we combine a genetically engineered THP-1 monocytic model with ex vivo analyses of blood and tissue samples from VEXAS patients to investigate the consequences of the canonical UBA1M41V mutation. We show that UBA1-mutated monocytes exhibit TNF--induced cell death, characterized by RIPK1 phosphorylation, and MLKL-and caspase-8-mediated cell death. This is associated with defective transcriptional induction of NF-{kappa}B target genes and reduced cFLIP(L) expression in response to TNF-. Monocytes also display blunted cytokine responses to multiple Toll-like receptor (TLR) agonists despite preserved TLR expression, linked to an impaired NF-{kappa}B response. UBA1M41V-derived macrophages exhibit an inflammatory transcriptional profile and increased secretion of chemokines that promote monocyte recruitment. We demonstrate that these UBA1M41V macrophages display impaired efferocytosis due to lysosomal dysfunction. Together, these findings reveal a pathogenic axis in VEXAS syndrome linking UBA1 loss of function and defective ubiquitination to RIPK1-mediated inflammatory cell death, impaired antimicrobial signaling, and defective resolution mechanisms. Our study provides novel mechanistic insights into the myeloid dysfunction that drives inflammation and cytopenia in VEXAS and highlights the necroptosis and efferocytosis pathways as potential therapeutic targets. Key points1/ UBA1-mutated monocytes are susceptible to RIPK1 dependent cell death and display impaired NF-{kappa}B-mediated cytokine responses to TLR agonists. 2/ UBA1-mutated macrophages promote inflammation and chemokine-mediated monocyte recruitment, while exhibiting defective efferocytosis.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Characterization of a maintainable human myeloid model of VEXAS syndrome with enhanced TNF-induced cell death and DAMP release
Yuma Sakamoto, Nobuyasu Baba, … Tomoyuki Mukai·bioRxiv·Sep 14, 2026
- Disturbing immune homeostasis by neutrophil loss of Uba1 induces VEXAS-like autoinflammatory disease in mice
Ge Dong, Jingjing Liu, … Zhigang Cai·Journal of Clinical InvestigationPeer-reviewed·Sep 4, 2025
- RIPK3-RNASE1 axis as a potential therapeutic and clinical monitoring target in VEXAS syndrome
Kana Higashitani, Tatsuma Ban, … Tomohiko Tamura·bioRxiv·Feb 6, 2026
- Single-cell genotype-phenotype mapping identifies therapeutic vulnerabilities in VEXAS syndrome
Saravanan Ganesan, Rebecca M. Murray, … Dan Avi Landau·bioRxiv·May 19, 2024
- Cell autonomous inflammation in VEXAS is mediated by cGAS-STING
Samuel J. Magaziner, Jason C. Collins, … David B. Beck·bioRxiv·May 29, 2026
- Shared and Distinct Mechanisms of UBA1 Inactivation Across Different Diseases
J. C. Collins, S. J. Magaziner, … A. Werner·bioRxiv·Oct 10, 2023